Last reviewed · How we verify
BCMA CAR-T or CD19 CAR-T or CD19×BCMA — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BCMA CAR-T or CD19 CAR-T or CD19×BCMA (BCMA CAR-T or CD19 CAR-T or CD19×BCMA) — Hebei Senlang Biotechnology Inc., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BCMA CAR-T or CD19 CAR-T or CD19×BCMA TARGET | BCMA CAR-T or CD19 CAR-T or CD19×BCMA | Hebei Senlang Biotechnology Inc., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BCMA CAR-T or CD19 CAR-T or CD19×BCMA CI watch — RSS
- BCMA CAR-T or CD19 CAR-T or CD19×BCMA CI watch — Atom
- BCMA CAR-T or CD19 CAR-T or CD19×BCMA CI watch — JSON
- BCMA CAR-T or CD19 CAR-T or CD19×BCMA alone — RSS
Cite this brief
Drug Landscape (2026). BCMA CAR-T or CD19 CAR-T or CD19×BCMA — Competitive Intelligence Brief. https://druglandscape.com/ci/bcma-car-t-or-cd19-car-t-or-cd19-bcma. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab